(Q34051079)

30 July 2017

title

Rivastigmine in Alzheimer's disease and Parkinson's disease dementia: an ADAS-cog factor analysis (English)

1 reference

Parkinson's disease dementia

30 July 2017

0 references

0 references

1 reference

ChEBI release 2020-05-28

1 reference

1 reference

1

Daniel Weintraub

1 reference

30 July 2017

Monique Somogyi

2

1 reference

30 July 2017

Xiangyi Meng

series ordinal

3

1 reference

30 July 2017

language of work or name

English

0 references

publication date

1 September 2011

1 reference

American Journal of Alzheimer's Disease & Other Dementias

30 July 2017

published in

1 reference

30 July 2017

volume

26

1 reference

30 July 2017

issue

6

1 reference

30 July 2017

page(s)

443-449

1 reference

A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease–– rivastigmine patchversus capsule

30 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1177%2F1533317511424892

Efficacy and safety of rivastigmine in patients with Alzheimer's disease: international randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511424892

Rivastigmine for dementia associated with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511424892

A new rating scale for Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511424892

Evaluation of dementia rating scales in Parkinson's disease dementia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511424892

Reviews: Effects of transdermal rivastigmine on ADAS-cog items in mild-to-moderate Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511424892

Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511424892

Effects of oral rivastigmine on cognitive domains in mild-to-moderate Alzheimer's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511424892

Evaluating rivastigmine in mild-to-moderate Parkinson's disease dementia using ADAS-cog items.

21 January 2018

1 reference

https://api.crossref.org/works/10.1177%2F1533317511424892

21 January 2018

Identifiers

DOI

10.1177/1533317511424892

1 reference

30 July 2017

1 reference